JP2014528714A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014528714A5 JP2014528714A5 JP2014530731A JP2014530731A JP2014528714A5 JP 2014528714 A5 JP2014528714 A5 JP 2014528714A5 JP 2014530731 A JP2014530731 A JP 2014530731A JP 2014530731 A JP2014530731 A JP 2014530731A JP 2014528714 A5 JP2014528714 A5 JP 2014528714A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- isolated
- seq
- purified
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cells Anatomy 0.000 claims 26
- 229920001184 polypeptide Polymers 0.000 claims 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims 13
- 102000004169 proteins and genes Human genes 0.000 claims 12
- 108090000623 proteins and genes Proteins 0.000 claims 12
- 108020004707 nucleic acids Proteins 0.000 claims 10
- 150000007523 nucleic acids Chemical class 0.000 claims 10
- 239000000427 antigen Substances 0.000 claims 9
- 108091007172 antigens Proteins 0.000 claims 9
- 102000038129 antigens Human genes 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 8
- 102000004965 antibodies Human genes 0.000 claims 7
- 108090001123 antibodies Proteins 0.000 claims 7
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 6
- 238000003259 recombinant expression Methods 0.000 claims 6
- 206010025650 Malignant melanoma Diseases 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010017758 Gastric cancer Diseases 0.000 claims 2
- 206010024324 Leukaemias Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 210000003171 Lymphocytes, Tumor-Infiltrating Anatomy 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 210000001635 Urinary Tract Anatomy 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 201000009251 multiple myeloma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 108010035452 HLA-A1 Antigen Proteins 0.000 claims 1
- 108010007655 HLA-C*70 antigen Proteins 0.000 claims 1
- 210000004698 Lymphocytes Anatomy 0.000 claims 1
- 108091008153 T cell receptors Proteins 0.000 claims 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 230000000295 complement Effects 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037240 fusion proteins Human genes 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 239000011886 peripheral blood Substances 0.000 claims 1
Claims (34)
- ａ）ＨＬＡ−Ａ１に関連してメラノーマ抗原ファミリーＡ（ＭＡＧＥ Ａ）−３、又は、ｂ）ＨＬＡ−Ｃｗ７に関連してＭＡＧＥ−Ａ１２に対する抗原特異性を有する、単離又は精製されたＴ細胞受容体（ＴＣＲ）。
- ａ）ＥＶＤＰＩＧＨＬＹ（配列番号２）を含むＭＡＧＥ−Ａ３エピトープ、又は、ｂ）ＶＲＩＧＨＬＹＩＬ（配列番号４）を含むＭＡＧＥ−Ａ１２エピトープに対する抗原特異性を有する、請求項１の単離又は精製されたＴＣＲ。
- 配列番号５〜１０、１６〜２１、２６〜３１、又は３６〜４１のアミノ酸配列を含む、請求項２の単離又は精製されたＴＣＲ。
- 配列番号１１〜１２、２２〜２３、３２〜３３、又は４２〜４３のアミノ酸配列を含む、請求項３の単離又は精製されたＴＣＲ。
- 配列番号１３〜１４、２４〜２５、３４〜３５、又は４４〜４５のアミノ酸配列を含む、請求項４の単離又は精製されたＴＣＲ。
- 請求項１〜５のいずれか１項のＴＣＲの機能部分を含む単離又は精製されたポリペプチドであって、機能部分が、配列番号５〜１０、１６〜２１、２６〜３１、又は３６〜４１のアミノ酸配列を含む、ポリペプチド。
- 部分が、配列番号１１〜１２、２２〜２３、３２〜３３、又は４２〜４３のアミノ酸配列を含む、請求項６の単離又は精製されたポリペプチド。
- 部分が、配列番号１３〜１４、２４〜２５、３４〜３５、又は４４〜４５のアミノ酸配列を含む、請求項７の単離又は精製されたポリペプチド。
- 請求項６〜８のいずれか１項のポリペプチドのうち少なくとも１つを含む、単離又は精製されたタンパク質。
- 配列番号５〜７、１６〜１８、２６〜２８、又は３６〜３８のアミノ酸配列を含む第一のポリペプチド鎖；および
配列番号８〜１０、１９〜２１、２９〜３１、又は３９〜４１のアミノ酸配列を含む第二のポリペプチド鎖を含む、請求項９の単離又は精製されたタンパク質。 - 配列番号１１、２２、３２、又は４２のアミノ酸配列を含む第一のポリペプチド鎖；および
配列番号１２、２３、３３、又は４３のアミノ酸配列を含む第二のポリペプチド鎖を含む、請求項１０の単離又は精製されたタンパク質。 - 配列番号１３、２４、３４、又は４４のアミノ酸配列を含む第一のポリペプチド鎖；および
配列番号１４、２５、３５、又は４５のアミノ酸配列を含む第二のポリペプチド鎖を含む、請求項１１の単離又は精製されたタンパク質。 - タンパク質が融合タンパク質である、請求項９〜１２のいずれか１項のタンパク質。
- タンパク質が組換え抗体である、請求項９〜１３のいずれか１項のタンパク質。
- 請求項１〜５のいずれか１項のＴＣＲ、請求項６〜８のいずれか１項のポリペプチド、又は請求項９〜１４のいずれか１項のタンパク質をコードするヌクレオチド配列を含む、単離又は精製された核酸。
- 配列番号４６〜４９のいずれか１つを含むヌクレオチド配列を含む、請求項１５の核酸。
- 請求項１６の核酸のヌクレオチド配列に対して相補的なヌクレオチド配列を含む、単離又は精製された核酸。
- 請求項１５〜１７のいずれか１項の核酸のヌクレオチド配列に対し、ストリンジェントな条件下でハイブリダイズするヌクレオチド配列を含む、単離又は精製された核酸
- 請求項１５〜１８のいずれか１項の核酸を含む、組換え発現ベクター。
- 請求項１９の組換え発現ベクターを含む、単離された宿主細胞。
- 細胞が末梢血リンパ球（ＰＢＬ）である、請求項２０の単離された宿主細胞。
- ＰＢＬがＴ細胞である、請求項２１の単離された宿主細胞。
- 細胞が、腫瘍浸潤リンパ球（ＴＩＬ）である、請求項２０の単離された宿主細胞。
- 請求項２０〜２３のいずれか１項の少なくとも１つの宿主細胞を含む、細胞集団。
- 請求項１〜５のいずれか１項のＴＣＲの機能部分に特異的に結合する抗体、又はその抗原結合部分であって、機能部分が、配列番号５〜１０、１６〜２１、２６〜３１、又は３６〜４１のアミノ酸配列を含む、抗体、又はその抗原結合部分。
- 請求項１〜５のいずれか１項のＴＣＲ、請求項６〜８のいずれか１項のポリペプチド、請求項９〜１４のいずれか１項のタンパク質、請求項１５〜１８のいずれか１項の核酸、請求項１９の組換え発現ベクター、請求項２０〜２３のいずれか１項の宿主細胞、請求項２４の細胞集団、又は請求項２５の抗体若しくはその抗原結合部分、および医薬的に許容される担体を含む、医薬組成物。
- 宿主における癌の存在を検出する方法であって：
（ｉ） 癌細胞を含む試料を、請求項１〜５のいずれか１項のＴＣＲ、請求項６〜８のいずれか１項のポリペプチド、請求項９〜１４のいずれか１項のタンパク質、請求項１５〜１８のいずれか１項の核酸、請求項１９の組換え発現ベクター、請求項２０〜２３のいずれか１項の宿主細胞、請求項２４の細胞集団、又は請求項２５の抗体、若しくはその抗原結合部分を接触させることによって、複合体を形成すること、および
（ｉｉ） 複合体を検出すること
を含み、
複合体の検出が、宿主における癌の存在を表す、方法。 - 癌が、メラノーマ、乳癌、白血病、甲状腺癌、胃癌、膵臓癌、肝臓癌、肺癌、卵巣癌、多発性骨髄腫、食道癌、腎臓癌、頭部癌、頸部癌、前立腺癌、又は尿路上皮癌である、請求項２７の方法。
- 宿主細胞が、宿主に対して自己の細胞である、請求項２７又は２８の方法。
- 集団の細胞が、宿主に対して自己の細胞である、請求項２７又は２８の方法。
- 宿主において癌を治療又は予防するための、請求項１〜５のいずれか１項のＴＣＲ、請求項６〜８のいずれか１項のポリペプチド、請求項９〜１４のいずれか１項のタンパク質、請求項１５〜１８のいずれか１項の核酸、請求項１９の組換え発現ベクター、請求項２０〜２３のいずれか１項の宿主細胞、請求項２４の細胞集団、請求項２５の抗体若しくはその抗原結合部分、又は請求項２６の医薬組成物。
- 癌が、メラノーマ、乳癌、白血病、甲状腺癌、胃癌、膵臓癌、肝臓癌、肺癌、卵巣癌、多発性骨髄腫、食道癌、腎臓癌、頭部癌、頸部癌、前立腺癌、又は尿路上皮癌である、請求項３１のＴＣＲ、ポリペプチド、タンパク質、核酸、組換え発現ベクター、宿主細胞、細胞集団、抗体若しくはその抗原結合部分、又は医薬組成物。
- 宿主細胞が、宿主に対して自己の細胞である、請求項３１又は３２の宿主細胞。
- 集団の細胞が、宿主に対して自己の細胞である、請求項３１又は３２の細胞集団。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161535086P | 2011-09-15 | 2011-09-15 | |
| US61/535,086 | 2011-09-15 | ||
| PCT/US2012/054623 WO2013039889A1 (en) | 2011-09-15 | 2012-09-11 | T cell receptors recognizing hla-a1- or hla-cw7-restricted mage |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018187094A Division JP6855426B2 (ja) | 2011-09-15 | 2018-10-02 | Ｈｌａ−ａ１−又はｈｌａ−ｃｗ７−拘束性ｍａｇｅを認識するｔ細胞受容体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014528714A JP2014528714A (ja) | 2014-10-30 |
| JP2014528714A5 true JP2014528714A5 (ja) | 2015-11-05 |
| JP6415322B2 JP6415322B2 (ja) | 2018-10-31 |
Family
ID=46881176
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014530731A Active JP6415322B2 (ja) | 2011-09-15 | 2012-09-11 | Ｈｌａ−ａ１−又はｈｌａ−ｃｗ７−拘束性ｍａｇｅを認識するｔ細胞受容体 |
| JP2018187094A Active JP6855426B2 (ja) | 2011-09-15 | 2018-10-02 | Ｈｌａ−ａ１−又はｈｌａ−ｃｗ７−拘束性ｍａｇｅを認識するｔ細胞受容体 |
| JP2021043845A Active JP7149364B2 (ja) | 2011-09-15 | 2021-03-17 | Ｈｌａ－ａ１－又はｈｌａ－ｃｗ７－拘束性ｍａｇｅを認識するｔ細胞受容体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018187094A Active JP6855426B2 (ja) | 2011-09-15 | 2018-10-02 | Ｈｌａ−ａ１−又はｈｌａ−ｃｗ７−拘束性ｍａｇｅを認識するｔ細胞受容体 |
| JP2021043845A Active JP7149364B2 (ja) | 2011-09-15 | 2021-03-17 | Ｈｌａ－ａ１－又はｈｌａ－ｃｗ７－拘束性ｍａｇｅを認識するｔ細胞受容体 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20140378389A1 (ja) |
| EP (3) | EP3766896A1 (ja) |
| JP (3) | JP6415322B2 (ja) |
| CN (2) | CN103974974A (ja) |
| AU (2) | AU2012309830B2 (ja) |
| CA (2) | CA3114877C (ja) |
| ES (2) | ES2689512T3 (ja) |
| IL (4) | IL290105B2 (ja) |
| PL (2) | PL2755997T3 (ja) |
| PT (2) | PT2755997T (ja) |
| SI (2) | SI3392270T1 (ja) |
| WO (1) | WO2013039889A1 (ja) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7340638B2 (ja) | 2016-06-27 | 2023-09-07 | ジュノー セラピューティクス インコーポレイテッド | Ｍｈｃ－ｅ拘束性エピトープ、結合分子ならびに関連する方法および使用 |
Families Citing this family (110)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN2014DN06624A (ja) | 2005-10-18 | 2015-07-10 | Univ Colorado | |
| EP2285832B1 (en) | 2008-05-16 | 2020-08-26 | Taiga Biotechnologies, Inc. | Antibodies and processes for preparing the same |
| CN104353066B (zh) | 2008-08-28 | 2017-05-10 | 泰加生物工艺学公司 | Myc的调节剂、其使用方法和鉴别调节myc的试剂的方法 |
| PL2755997T3 (pl) | 2011-09-15 | 2019-01-31 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Receptory komórek T rozpoznające MAGE ograniczone do HLA-A1 lub HLA-CW7 |
| EP3868387A1 (en) | 2012-07-20 | 2021-08-25 | Taiga Biotechnologies, Inc. | Enhanced reconstitution and autoreconstitution of the hematopoietic compartment |
| CA2884743C (en) | 2012-09-14 | 2023-03-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors recognizing mhc class ii-restricted mage-a3 |
| US10272115B2 (en) | 2013-03-11 | 2019-04-30 | Taiga Biotechnologies, Inc. | Production and use of red blood cells |
| US10801070B2 (en) | 2013-11-25 | 2020-10-13 | The Broad Institute, Inc. | Compositions and methods for diagnosing, evaluating and treating cancer |
| WO2015085147A1 (en) | 2013-12-05 | 2015-06-11 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
| BR112016014410A2 (pt) | 2013-12-20 | 2018-02-20 | The Broad Institute Inc. | terapia de combinação com vacina de neoantígeno |
| EP3201321A1 (en) | 2014-10-02 | 2017-08-09 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating t cells having antigenic specificity for a cancer-specific mutation |
| ES2924709T3 (es) * | 2014-10-02 | 2022-10-10 | Us Health | Métodos de aislamiento de receptores de células T que tienen especificidad antigénica para una mutación específica de cáncer |
| GB201417803D0 (en) | 2014-10-08 | 2014-11-19 | Adaptimmune Ltd | T cell receptors |
| CA2965521A1 (en) * | 2014-10-31 | 2016-05-06 | Baylor College Of Medicine | Survivin specific t-cell receptor targeting tumor but not t cells |
| EP3234193B1 (en) | 2014-12-19 | 2020-07-15 | Massachusetts Institute of Technology | Molecular biomarkers for cancer immunotherapy |
| US10993997B2 (en) | 2014-12-19 | 2021-05-04 | The Broad Institute, Inc. | Methods for profiling the t cell repertoire |
| JP6894380B2 (ja) * | 2015-04-27 | 2021-06-30 | アブビトロ， エルエルシー | 治療用薬剤および疾患特異的抗原をシーケンシング、判定、ペアリングおよび検証する方法 |
| MY190974A (en) | 2015-05-20 | 2022-05-25 | Massachusetts Gen Hospital | Shared neoantigens |
| WO2016205749A1 (en) | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Novel crispr enzymes and systems |
| US10556940B2 (en) | 2015-09-15 | 2020-02-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors recognizing HLA-Cw8 restricted mutated KRAS |
| CN108290940B (zh) * | 2015-10-01 | 2021-12-07 | 圣拉斐尔医院有限公司 | Tcr及其用途 |
| WO2017069958A2 (en) | 2015-10-09 | 2017-04-27 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
| WO2017070042A1 (en) | 2015-10-20 | 2017-04-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing t cell populations using akt inhibitors |
| WO2017075465A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3 |
| WO2017075451A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1 |
| WO2017075478A2 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures |
| EP3377086B1 (en) | 2015-11-19 | 2024-05-01 | The Brigham and Women's Hospital, Inc. | Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity |
| WO2017139199A1 (en) | 2016-02-10 | 2017-08-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inducible arginase |
| PT3440105T (pt) | 2016-04-08 | 2022-05-31 | Immunocore Ltd | Recetores de células t |
| AU2017254477A1 (en) | 2016-04-18 | 2018-11-01 | Jennifer G. ABELIN | Improved HLA epitope prediction |
| DK3448882T3 (da) * | 2016-04-26 | 2022-02-21 | Us Health | Anti-kk-lc-1-t-cellereceptorer |
| LT3494133T (lt) * | 2016-08-02 | 2022-12-12 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Anti-kras-g12d t ląstelės receptoriai |
| WO2018035364A1 (en) | 2016-08-17 | 2018-02-22 | The Broad Institute Inc. | Product and methods useful for modulating and evaluating immune responses |
| WO2018049025A2 (en) | 2016-09-07 | 2018-03-15 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses |
| WO2018067991A1 (en) | 2016-10-07 | 2018-04-12 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
| WO2018097951A1 (en) | 2016-11-22 | 2018-05-31 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mage-a3/a6 antibodies |
| CN113307858A (zh) | 2016-12-02 | 2021-08-27 | 泰加生物工艺学公司 | 纳米颗粒调配物 |
| DE102016123847B3 (de) | 2016-12-08 | 2018-04-05 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie |
| KR20240007775A (ko) * | 2016-12-08 | 2024-01-16 | 이매틱스 바이오테크놀로지스 게엠베하 | T 세포 수용체 및 이를 사용하는 면역 요법 |
| EP3574116A1 (en) | 2017-01-24 | 2019-12-04 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
| WO2018148224A1 (en) | 2017-02-07 | 2018-08-16 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Phospholipid ether (ple) car t cell tumor targeting (ctct) agents |
| CN116693695A (zh) | 2017-02-12 | 2023-09-05 | 百欧恩泰美国公司 | 基于hla的方法和组合物及其用途 |
| EP3589295A4 (en) | 2017-02-28 | 2020-11-04 | Endocyte, Inc. | COMPOSITIONS AND METHODS OF T CAR LYMPHOCYTE THERAPY |
| WO2018183908A1 (en) | 2017-03-31 | 2018-10-04 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating ovarian tumors |
| EP3606518A4 (en) | 2017-04-01 | 2021-04-07 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR DETECTION AND MODULATION OF IMMUNOTHERAPY RESISTANCE GENE SIGNATURE IN CANCER |
| US20200071773A1 (en) | 2017-04-12 | 2020-03-05 | Massachusetts Eye And Ear Infirmary | Tumor signature for metastasis, compositions of matter methods of use thereof |
| EP3612629A1 (en) | 2017-04-18 | 2020-02-26 | The Broad Institute, Inc. | Compositions for detecting secretion and methods of use |
| US11897953B2 (en) | 2017-06-14 | 2024-02-13 | The Broad Institute, Inc. | Compositions and methods targeting complement component 3 for inhibiting tumor growth |
| US10149898B2 (en) | 2017-08-03 | 2018-12-11 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
| SG11202000612TA (en) | 2017-08-03 | 2020-02-27 | Taiga Biotechnologies Inc | Methods and compositions for the treatment of melanoma |
| WO2019036688A1 (en) * | 2017-08-18 | 2019-02-21 | Gritstone Oncology, Inc. | ANTIGEN BINDING PROTEINS TARGETING SHARED ANTIGENS |
| WO2019060746A1 (en) | 2017-09-21 | 2019-03-28 | The Broad Institute, Inc. | SYSTEMS, METHODS, AND COMPOSITIONS FOR THE TARGETED EDITING OF NUCLEIC ACIDS |
| WO2019075055A1 (en) | 2017-10-11 | 2019-04-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | METHODS FOR PRODUCING T-CELL POPULATIONS USING P38 MAPK INHIBITORS |
| WO2019084055A1 (en) | 2017-10-23 | 2019-05-02 | Massachusetts Institute Of Technology | CLASSIFICATION OF GENETIC VARIATION FROM UNICELLULAR TRANSCRIPTOMS |
| US20210363260A1 (en) | 2017-11-13 | 2021-11-25 | The Broad Institute, Inc. | Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway |
| US11793867B2 (en) | 2017-12-18 | 2023-10-24 | Biontech Us Inc. | Neoantigens and uses thereof |
| JP7417542B2 (ja) | 2018-01-22 | 2024-01-18 | シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） | Ｃａｒ ｔ細胞の使用方法 |
| CA3090512A1 (en) | 2018-02-09 | 2019-08-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Tethered interleukin-15 and interleukin-21 |
| KR20210003767A (ko) * | 2018-04-19 | 2021-01-12 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | Mage-b2 특이성을 갖는 t 세포 수용체 및 이의 용도 |
| US20210071141A1 (en) | 2018-04-24 | 2021-03-11 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Methods of producing t cell populations using hydroxycitric acid and/or a salt thereof |
| US11957695B2 (en) | 2018-04-26 | 2024-04-16 | The Broad Institute, Inc. | Methods and compositions targeting glucocorticoid signaling for modulating immune responses |
| US20210371932A1 (en) | 2018-06-01 | 2021-12-02 | Massachusetts Institute Of Technology | Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients |
| US20210355522A1 (en) | 2018-08-20 | 2021-11-18 | The Broad Institute, Inc. | Inhibitors of rna-guided nuclease activity and uses thereof |
| WO2020068304A2 (en) | 2018-08-20 | 2020-04-02 | The Broad Institute, Inc. | Inhibitors of rna-guided nuclease target binding and uses thereof |
| WO2020041387A1 (en) | 2018-08-20 | 2020-02-27 | The Brigham And Women's Hospital, Inc. | Degradation domain modifications for spatio-temporal control of rna-guided nucleases |
| WO2020072700A1 (en) | 2018-10-02 | 2020-04-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
| US20210379057A1 (en) | 2018-10-16 | 2021-12-09 | Massachusetts Institute Of Technology | Nutlin-3a for use in treating a mycobacterium tuberculosis infection |
| WO2020092455A2 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Car t cell transcriptional atlas |
| GB201819540D0 (en) * | 2018-11-30 | 2019-01-16 | Adaptimmune Ltd | T cell modification |
| WO2020131586A2 (en) | 2018-12-17 | 2020-06-25 | The Broad Institute, Inc. | Methods for identifying neoantigens |
| SG11202106678PA (en) | 2018-12-21 | 2021-07-29 | Biontech Us Inc | Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cells |
| US11739156B2 (en) | 2019-01-06 | 2023-08-29 | The Broad Institute, Inc. Massachusetts Institute of Technology | Methods and compositions for overcoming immunosuppression |
| AU2020209991A1 (en) * | 2019-01-17 | 2021-08-19 | Immunocore Limited | Formulations |
| US20220154282A1 (en) | 2019-03-12 | 2022-05-19 | The Broad Institute, Inc. | Detection means, compositions and methods for modulating synovial sarcoma cells |
| US20220142948A1 (en) | 2019-03-18 | 2022-05-12 | The Broad Institute, Inc. | Compositions and methods for modulating metabolic regulators of t cell pathogenicity |
| WO2020236967A1 (en) | 2019-05-20 | 2020-11-26 | The Broad Institute, Inc. | Random crispr-cas deletion mutant |
| WO2020243371A1 (en) | 2019-05-28 | 2020-12-03 | Massachusetts Institute Of Technology | Methods and compositions for modulating immune responses |
| PE20220231A1 (es) | 2019-06-25 | 2022-02-07 | Gilead Sciences Inc | Proteinas de fusion flt3l-fc y metodos de uso |
| JP2022538974A (ja) | 2019-06-26 | 2022-09-07 | マサチューセッツ インスチテュート オブ テクノロジー | 免疫調節融合タンパク質－金属水酸化物錯体およびその方法 |
| WO2021030627A1 (en) | 2019-08-13 | 2021-02-18 | The General Hospital Corporation | Methods for predicting outcomes of checkpoint inhibition and treatment thereof |
| WO2021041922A1 (en) | 2019-08-30 | 2021-03-04 | The Broad Institute, Inc. | Crispr-associated mu transposase systems |
| WO2021061648A1 (en) | 2019-09-23 | 2021-04-01 | Massachusetts Institute Of Technology | Methods and compositions for stimulation of endogenous t cell responses |
| US11981922B2 (en) | 2019-10-03 | 2024-05-14 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment |
| US11793787B2 (en) | 2019-10-07 | 2023-10-24 | The Broad Institute, Inc. | Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis |
| US11844800B2 (en) | 2019-10-30 | 2023-12-19 | Massachusetts Institute Of Technology | Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia |
| US11865168B2 (en) | 2019-12-30 | 2024-01-09 | Massachusetts Institute Of Technology | Compositions and methods for treating bacterial infections |
| CA3169451A1 (en) | 2020-02-14 | 2021-08-19 | Jounce Therapeutics, Inc. | Antibodies and fusion proteins that bind to ccr8 and uses thereof |
| KR20220166282A (ko) | 2020-03-10 | 2022-12-16 | 매사추세츠 인스티튜트 오브 테크놀로지 | 조작된 기억-유사 nk 세포 및 이의 조성물을 생성하기 위한 방법 |
| JP2020143057A (ja) * | 2020-04-01 | 2020-09-10 | アメリカ合衆国 | がん特異的突然変異に対し抗原特異性を有するｔ細胞受容体を単離する方法 |
| US20210340524A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof |
| WO2021221782A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Chimeric antigen receptor-targeting ligands and uses thereof |
| CN111693702A (zh) * | 2020-07-11 | 2020-09-22 | 成都益安博生物技术有限公司 | 一种黑色素瘤的外周血tcr标志物及其检测试剂盒和应用 |
| CN116583537A (zh) | 2020-09-08 | 2023-08-11 | 美国卫生和人力服务部 | 与对过继细胞疗法的应答相关的t细胞表型 |
| JP2023542208A (ja) * | 2020-09-24 | 2023-10-05 | メディジーン イミュノテラピーズ ゲーエムベーハー | Ｍａｇｅ－ａ３特異的ｔ細胞受容体およびその使用 |
| TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| EP4243937A2 (en) | 2020-11-13 | 2023-09-20 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Enhanced antigen reactivity of immune cells expressing a mutant non-signaling cd3 zeta chain |
| US20240150711A1 (en) | 2021-03-01 | 2024-05-09 | Dana-Farber Cancer Institute, Inc. | Personalized redirection and reprogramming of t cells for precise targeting of tumors |
| TW202313094A (zh) | 2021-05-18 | 2023-04-01 | 美商基利科學股份有限公司 | 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法 |
| TW202330504A (zh) | 2021-10-28 | 2023-08-01 | 美商基利科學股份有限公司 | 嗒𠯤—３（２ｈ）—酮衍生物 |
| AU2022376954A1 (en) | 2021-10-29 | 2024-05-02 | Gilead Sciences, Inc. | Cd73 compounds |
| US20230242508A1 (en) | 2021-12-22 | 2023-08-03 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| WO2023122581A2 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| WO2023130040A2 (en) | 2021-12-31 | 2023-07-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell therapy with vaccination as a combination immunotherapy against cancer |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| EP4245756A1 (en) | 2022-03-17 | 2023-09-20 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202400138A (zh) | 2022-04-21 | 2024-01-01 | 美商基利科學股份有限公司 | Ｋｒａｓ ｇ１２ｄ調節化合物 |
| WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
| WO2024015743A1 (en) * | 2022-07-11 | 2024-01-18 | Board Of Regents, The University Of Texas System | Peptides and engineered t cell receptors targeting vcy antigen and methods of use |
| WO2024077256A1 (en) | 2022-10-07 | 2024-04-11 | The General Hospital Corporation | Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins |
| CN117986350A (zh) * | 2023-02-23 | 2024-05-07 | 暨南大学 | 一种识别mage-a3抗原短肽的t细胞受体及其应用 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4450150A (en) | 1973-05-17 | 1984-05-22 | Arthur D. Little, Inc. | Biodegradable, implantable drug delivery depots, and method for preparing and using the same |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| IN165717B (ja) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| CA2072356A1 (en) | 1989-12-29 | 1991-06-30 | James L. Urban | Diagnosis and treatment of diseases |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| CA2089661C (en) | 1990-08-29 | 2007-04-03 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| JP3266311B2 (ja) | 1991-05-02 | 2002-03-18 | 生化学工業株式会社 | 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤 |
| US5662907A (en) | 1992-08-07 | 1997-09-02 | Cytel Corporation | Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes |
| US5405940A (en) * | 1992-08-31 | 1995-04-11 | Ludwig Institute For Cancer Research | Isolated nonapeptides derived from MAGE genes and uses thereof |
| CA2143335C (en) | 1992-08-31 | 2000-03-14 | Thierry Boon-Falleur | Isolated nonapeptide derived from mage-3 gene and presented by hla-a1, and uses thereof |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| DE69533295T3 (de) | 1994-02-16 | 2009-07-16 | The Government Of The United States Of America, As Represented By The Secretary, The Department Of Health And Human Services | Melanoma-assoziierte Antigene, Epitope davon und Impstoffe gegen Melanoma |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| DE19625191A1 (de) | 1996-06-24 | 1998-01-02 | Boehringer Mannheim Gmbh | Nierenkarzinom-spezifische T-Zellen |
| IL127142A0 (en) * | 1998-11-19 | 1999-09-22 | Yeda Res & Dev | Immune cells having predefined biological specificity |
| US6897288B1 (en) | 1999-10-19 | 2005-05-24 | Ludwig Institute For Cancer Research | Mage-A12 antigenic peptides and uses thereof |
| CN1402782A (zh) * | 1999-10-19 | 2003-03-12 | 路德维哥癌症研究院 | Mage－a12抗原肽及其应用 |
| CA2398136A1 (en) | 2000-02-08 | 2001-08-16 | The Penn State Research Foundation | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
| WO2001074847A2 (en) * | 2000-03-30 | 2001-10-11 | The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services | T-cell epitope of mage-12 and related nucleic acids, vectors, cells, compositions and methods of inducing an immune response to cancer |
| WO2005019258A2 (en) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| JP5079697B2 (ja) * | 2005-08-05 | 2012-11-21 | ヘルムホルツ ツェントラム ミュンヘン ドイチェス フォーシュングスツェントラム フュール ゲズントハイト ウント ウンヴェルト ゲーエムベーハー | 抗原特異的ｔ細胞の生成方法 |
| EP1930433B1 (en) | 2005-09-13 | 2016-03-16 | Mie University | T-cell receptor and nucleic acid encoding the receptor |
| US7820174B2 (en) * | 2006-02-24 | 2010-10-26 | The United States Of America As Represented By The Department Of Health And Human Services | T cell receptors and related materials and methods of use |
| JP5292550B2 (ja) * | 2007-03-23 | 2013-09-18 | 静岡県 | Ｔ細胞レセプターβ鎖遺伝子及びα鎖遺伝子 |
| US20100136597A1 (en) * | 2007-04-26 | 2010-06-03 | Nathalie Demotte | Method for modularting activity of t lymphocytes |
| KR101363928B1 (ko) | 2007-06-11 | 2014-02-19 | 고쿠리츠다이가쿠호진 미에다이가쿠 | 특이적 유전자 발현 방법 |
| GB0720118D0 (en) | 2007-10-15 | 2007-11-28 | Achour Adnane | Modified mhc class 1 binding peptides |
| WO2010075417A1 (en) * | 2008-12-23 | 2010-07-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Survivin specific t cell receptor for treating cancer |
| US8785601B2 (en) * | 2009-01-28 | 2014-07-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors and related materials and methods of use |
| GB0908613D0 (en) * | 2009-05-20 | 2009-06-24 | Immunocore Ltd | T Cell Reseptors |
| US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| EP2598528A1 (en) * | 2010-07-28 | 2013-06-05 | Immunocore Ltd. | T cell receptors |
| US9678061B2 (en) * | 2010-08-06 | 2017-06-13 | Ludwig-Maximilians-Universität München | Identification of T cell target antigens |
| WO2012054825A1 (en) * | 2010-10-22 | 2012-04-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mage-a3 t cell receptors and related materials and methods of use |
| PL2755997T3 (pl) | 2011-09-15 | 2019-01-31 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Receptory komórek T rozpoznające MAGE ograniczone do HLA-A1 lub HLA-CW7 |
-
2012
- 2012-09-11 PL PL12761862T patent/PL2755997T3/pl unknown
- 2012-09-11 EP EP20192082.4A patent/EP3766896A1/en active Pending
- 2012-09-11 ES ES12761862.7T patent/ES2689512T3/es active Active
- 2012-09-11 ES ES18175738T patent/ES2834070T3/es active Active
- 2012-09-11 EP EP12761862.7A patent/EP2755997B1/en active Active
- 2012-09-11 EP EP18175738.6A patent/EP3392270B1/en active Active
- 2012-09-11 CA CA3114877A patent/CA3114877C/en active Active
- 2012-09-11 IL IL290105A patent/IL290105B2/en unknown
- 2012-09-11 SI SI201231859T patent/SI3392270T1/sl unknown
- 2012-09-11 PT PT12761862T patent/PT2755997T/pt unknown
- 2012-09-11 CN CN201280055972.XA patent/CN103974974A/zh active Pending
- 2012-09-11 AU AU2012309830A patent/AU2012309830B2/en active Active
- 2012-09-11 PL PL18175738T patent/PL3392270T3/pl unknown
- 2012-09-11 CA CA2848209A patent/CA2848209C/en active Active
- 2012-09-11 US US14/344,354 patent/US20140378389A1/en not_active Abandoned
- 2012-09-11 CN CN201811170958.XA patent/CN109517055B/zh active Active
- 2012-09-11 PT PT181757386T patent/PT3392270T/pt unknown
- 2012-09-11 SI SI201231403T patent/SI2755997T1/sl unknown
- 2012-09-11 JP JP2014530731A patent/JP6415322B2/ja active Active
- 2012-09-11 WO PCT/US2012/054623 patent/WO2013039889A1/en active Application Filing
-
2014
- 2014-03-05 IL IL231323A patent/IL231323B/en active IP Right Grant
-
2017
- 2017-06-16 AU AU2017204103A patent/AU2017204103B2/en active Active
-
2018
- 2018-09-27 US US16/144,226 patent/US11306131B2/en active Active
- 2018-10-02 JP JP2018187094A patent/JP6855426B2/ja active Active
-
2019
- 2019-07-18 IL IL268157A patent/IL268157B/en active IP Right Grant
-
2021
- 2021-03-17 JP JP2021043845A patent/JP7149364B2/ja active Active
- 2021-03-25 IL IL281806A patent/IL281806B/en unknown
-
2022
- 2022-03-10 US US17/691,569 patent/US20220195008A1/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7340638B2 (ja) | 2016-06-27 | 2023-09-07 | ジュノー セラピューティクス インコーポレイテッド | Ｍｈｃ－ｅ拘束性エピトープ、結合分子ならびに関連する方法および使用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014528714A5 (ja) | ||
| EP3430030B1 (en) | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers | |
| TWI708788B (zh) | 雙特異性抗體 | |
| CN113227146B (zh) | 密蛋白18.2结合部分和其用途 | |
| JP2015525208A5 (ja) | ||
| JP2019512242A5 (ja) | ||
| JP2012100677A5 (ja) | ||
| JP2014500002A5 (ja) | ||
| JP2013056885A5 (ja) | ||
| JP2019511904A5 (ja) | ||
| US20150175712A1 (en) | Antagonist to an enzyme and/or a metabolite of the kynurenine pathway | |
| WO2013018885A1 (ja) | 膵臓癌の検出方法 | |
| WO2016011571A1 (en) | Bispecific antibody-mediated cancer therapy with cytokine-induced killer cell | |
| Ye et al. | Targeted photodynamic therapy of cancer using a novel gallium (III) tris (ethoxycarbonyl) corrole conjugated‐mAb directed against cancer/testis antigens 83 | |
| AU2020294797A1 (en) | Multi-chain chimeric polypeptides and uses thereof | |
| JP2018518474A (ja) | グリピカン−３に対する抗体並びにがん診断及び治療におけるそれらの使用 | |
| KR20220142975A (ko) | 조절 t 세포 표면 항원의 에피토프 및 이에 특이적으로 결합하는 항체 | |
| CN112601546A (zh) | Plap-car-效应细胞 | |
| WO2022134276A1 (zh) | 一种抗人骨桥蛋白的抗体及其应用 | |
| Liu et al. | Tip110 binding to U6 small nuclear RNA and its participation in pre-mRNA splicing | |
| JP4651495B2 (ja) | Ｉｓｇ１５タンパク質と特異的に反応するモノクローナル抗体及びそれを産生するハイブリドーマ並びに癌およびウイルス感染の検出方法 | |
| CN106957367B (zh) | 抗idh1 r132h抗体及其制备方法和用途 | |
| CN111087470B (zh) | 一种抗人CD47单克隆抗体7G4mAb及其应用 | |
| JP2017536821A5 (ja) | ||
| CN113272016A (zh) | 关于治疗实体肿瘤的工程化和非工程化γδ-T细胞的组合物和方法 |